The purpose of this paper was to define the histologic distrito the endemic (African) and sporadic forms of Burkitt lymbution, clinical features, and treatment response of childhood phoma, which differ in their clinical presentation, regional non-Hodgkin lymphoma (NHL) in northeastern Brazil. We incidence, association with Epstein-Barr virus, and biologic 
Between January 1980 and October 1987, a total of 98 chilfocused on these patients. The majority (n = 84) had advanced dren were diagnosed with non-Hodgkin lymphoma at the 
parental refusal/abandonment of therapy (10%). Epstein-Barr
Diagnostic imaging studies were performed as indicated.
virus (EBV) was detected in tumor cells from eight of the 11
The pathologic diagnosis was established by histologic Of the 98 patients evaluated during the study period, 92 had small noncleaved cell histology. There were only five cases of lymphoblastic lymphoma and one of large cell histology. Having confirmed the predominance of Burkitt lymIntroduction phoma among the pediatric patients with NHL, we then focused on these 92 cases. Records were reviewed to evaluate The non-Hodgkin lymphomas of childhood are predominantly clinical and biological features, type of treatment, and outhigh-grade extranodal tumors that include the lymphoblastic, come. When sufficient paraffin-embedded tumor tissue was large cell, and small noncleaved cell subtypes. 1 The relative available, in situ RNA/RNA cytohybridization using plasmids frequency of these subtypes varies with geographic location.
containing EBV-encoded small nuclear RNA was performed In the United States, the distribution is almost equal, 2 whereas at St Jude Children's Research Hospital to detect the presence small noncleaved cell tumors (Burkitt lymphoma) account for of Epstein-Barr virus DNA. 6 In these cases, the histologic diagthe majority of childhood NHLs in equatorial Africa. 3, 4 In nosis was also reviewed and confirmed by a pediatric hematonortheastern Brazil -an area in which we have established a pathologist at St Jude (CWB). cooperative clinical program -anecdotal evidence suggests an increased overall incidence of lymphoma. However, to our knowledge, there have been no reports focusing on pediatric Hodgkin or non-Hodgkin lymphomas in this region.
Treatment
We noted an apparent predominance of the small noncleaved cell histology among children treated for NHL at a There were two distinct treatment periods. From 1980 to major pediatric cancer center in Recife, Brazil. In the present 1983, all consenting patients were treated with induction study, we evaluated the accuracy of this clinical impression chemotherapy similar to that used in the LSA 2 L 2 regimen and assessed long-term treatment outcome. We also sought to described by Wollner et al, 7 followed by maintenance therapy determine the relationship of the small noncleaved cell cases with cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and 6-mercaptopurine. disease were treated with various regimens of lesser intensity.
Three patients with advanced stage disease were treated off protocol with multiagent chemotherapy.
Statistical analysis
We evaluated event-free survival (EFS), defined as the time from diagnosis to relapse, death, or last follow-up, using survival curves constructed by the Kaplan-Meier method.
8
Patients who did not demonstrate initial disease control (complete response) were treated as failures at time zero. The log-rank test was used to compare the EFS among patient subgroups.
9
Results

Clinical and biologic features
The 92 children diagnosed with Burkitt lymphoma represented 94% of all patients evaluated for non-Hodgkin lymphoma at this institution during the 7-year study period. There in age at diagnosis from 1 to 14 years (median = 5.5 years). Large abdominal masses were present at diagnosis in the majority of these cases (see Table 1 ). Only three patients LSA 2 L 2 regimen compared to other multiagent chemotherapy presented with jaw masses. Bone marrow disease was ident-(43 ± 9%, n = 44 and 43 ± 7%, n = 29, respectively, P = 0.95). ified in seven cases and central nervous system involvement Serum levels of lactic dehydrogenase (LDH) at diagnosis (malignant CSF pleocytosis or the presence of cranial nerve were related to outcome in the 42 cases for which this inforpalsies) was present in four cases. The majority of patients mation was available (Figure 2 ). The 16 children with a serum (n = 84) had advanced stage disease. Adequate paraffin-LDH greater than 500 U/l (upper limit of normal, 300 U/l) had embedded tumor tissue for EBV studies was available in 11 a significantly poorer 5-year EFS than the 26 patients with a cases. Of these, 8 (73%) were found to be EBV positive. There lower LDH (38 ± 11% vs 73 ± 8%; P = 0.0079). were no obvious differences in clinical presentation between
The outcome for all 92 children, including those who EBV-positive and EBV-negative cases.
stopped treatment early, is illustrated in Figure 3 . Long-term event-free survivors represent only 39% of the total group. The majority of deaths were in patients who developed sepsis
Treatment response
(25% of cases), who had relapsed or progressive disease Eight children were excluded from the analysis of event-free survival because of parental refusal or discontinuation of treatment prior to completion of induction therapy. Thus, EFS estimates are based on 84 patients. As shown in Figure 1 , there was a significant overall relationship between stage and treatment outcome (P = 0.0003). In a combined analysis, children with limited stage (I/II) disease had a significantly better treatment outcome than those with advanced stage (III/IV) disease (5-year EFS, 75 ± 14% vs 42 ± 6%; P Ͻ 0.04, exact log rank test). Among the advanced-stage group, there was no significant difference in the 5-year EFS for patients treated with the 
Figure 2
Treatment outcome, by serum lactic dehydrogenase (LDH) level, for children with Burkitt lymphoma treated in Recife, a Some patients had more than one site of involvement. b Presented as jaw masses in three cases.
Brazil.
was associated with a poor outcome in advanced stage sporadic cases treated on a Childrens Cancer Group (CCG) study. 13 The CCG comparison trial showed a significant advantage of COMP chemotherapy in patients with sporadic Burkitt lymphoma. A direct comparison of our result and that of the CCG is limited because the CCG report does not include outcome for Burkitt's NHL by LDH or by specific stage (ie III vs IV). However, for advanced stage patients as a whole (III and IV, collectively), the response to LSA 2 L 2 in the Recife patients may be better than for those in the CCG study (5-year EFS = 43 ± 7% vs 29 ± 7%, respectively). Of note, the apparent treatment advantage for children from Recife treated with LSA 2 L 2 may be underestimated in view of the high number of septic deaths in this region (Ϸ25%). There is insufficient data for direct treatment response comparisons of cases in Recife vs those in endemic areas.
Biologic differences also characterize the endemic and sporadic forms. Endemic Burkitt lymphomas express cell surface CD21 antigen but not CD10 (CALLA), while the converse is true for the sporadic subtype. In endemic cases, the chromosome 8 breakpoint in the 8;14 translocation is far upstream within the c-MYC gene (at either the first intron or exon) in sporadic cases. 10,11 Unfortunately, immunophenotyping and (22%), or who received no or minimal therapy due to parental molecular genetic studies are not available for the present serrefusal or early discontinuation of treatment (10%). The ies, although we have initiated such studies in newly diagremaining patients (4%) died of metabolic abnormalities nosed patients. In other parts of South America, however, (tumor lysis syndrome), surgical complications, cirrhosis or atypical biologic variants of Burkitt lymphoma have been cardiac dysfunction.
identified. For example, Butierrez et al 14 have identified a c-MYC breakpoint intermediate to that reported for the endemic and sporadic subtypes in Burkitt lymphomas from a variety of Discussion South American countries. Those authors also reported a 50% rate of EBV positivity in tumor cells, a proportion which is also The vast majority of non-Hodgkin lymphomas diagnosed in intermediate between typical reports for the two subtypes. In this series (94%) were of the small non-cleaved cell (Burkitt) the present series, we were able to study 11 cases, eight of subtype. This finding would suggest that Burkitt lymphomas which (73%) were EBV positive -less than the 95% rate seen in northeastern Brazil may be of the endemic rather than the in endemic cases but greater than the 15% typically reported sporadic subtype. However, our review of clinical features for sporadic cases. The latter figure may be an underestimate, and treatment response indicates that these tumors may rephowever. Singh and colleagues 15 detected a mutant EBV genresent an intermediate or third subtype of Burkitt lymphoma.
ome segment integrated in the DNA of sporadic Burkitt lymThe contrasting clinicobiologic features of endemic and phomas in the United States that had been considered EBVsporadic Burkitt lymphoma have been well characnegative based on standard antigen screening. We are curterized. 4, 10, 11 There is a marked difference in reported average rently performing similar studies of the 'EBV negative' tumors annual incidence rates -10 per 100 000 children younger in northeastern Brazil to determine whether the actual frethan 16 years for the endemic (African) type but only 0.2 per quency of EBV association is even higher than that suggested 100 000 for the sporadic subtype. Current incidence figures by the present study. The relationship, if any, between EBV are not available for northeastern Brazil. Interestingly, an earlpositivity and variations in c-MYC breakpoint location also ier study of lymphomas in adults and children in this region 12 remains to be elucidated. concluded that the Burkitt subtype was extremely rare both in As in the US series, 2,4 a large tumor burden (defined by relative frequency and absolute numbers -a marked contrast either advanced stage or elevated serum LDH at diagnosis) with our findings. This difference is likely due to the small was predictive of a poorer treatment outcome for the patients number of children less than 15 years of age with non-Hodgtreated in Recife. Other factors that affected survival were kin lymphoma, included in the earlier study. However, socioeconomic and cultural in nature. For example, 25% of changes in predisposing environmental factors may have patients died of infectious complications, the majority after occurred during the interval between the two studies.
achieving remission from their lymphoma. We have observed In terms of clinical presentation, the Recife patients more a decrease in deaths from sepsis among NHL patients at the closely resemble the sporadic pattern. Jaw masses are very
Hospital Barao De Lucena in recent years, with the increased common in endemic Burkitt lymphoma (ෂ58% of cases) but availability of effective antibiotics and implementation of a rare in sporadic cases, which most often present with an more uniform approach to the management of fever and neuabdominal mass or nasopharyngeal tumor. In our series, jaw
tropenia. An additional problem faced in this region is achievinvolvement occurred in Ͻ3% of cases; 84% of patients ing parental consent and compliance. Refusal or early abanpresented with abdominal masses (compared to ෂ58% donment of therapy occurred in 10% of cases in our series. abdominal involvement in endemic cases). However, those
We hope that recently instituted patient education programs patients who received an adequate course of treatment responded surprisingly well to LSA 2 L 2 therapy -a regimen that will help resolve this problem, which is based largely in the
